title: The outcome of reduced intensity allogeneic stem cell transplantation and autologous stem cell transplantation when performed as a first transplant strategy in relapsed follicular lymphoma: an analysis from the Lymphoma Working Party of the EBMT.
abstract: Both auto-SCT and reduced intensity allo-SCT (RIST) are employed in the treatment of relapsed follicular lymphoma (FL). We have analysed the outcome of these two transplant procedures when used as a first transplant in this setting. We conducted a retrospective comparison of 726 patients who underwent an auto-SCT and 149 who underwent a RIST as a first transplant procedure for relapsed FL as reported to the Lymphoma Working Party of the European Bone Marrow Transplant. The non-relapse mortality (NRM) was significantly worse for patients undergoing a RIST (relative risk (RR) 4.0, P<0.001). The 1-year NRM was 15% for those undergoing a RIST compared with 3% for those undergoing an auto-SCT. Disease relapse or progression were significantly worse for those receiving an auto-SCT (RR 3.1, P<0.001). Patients undergoing a RIST had a 5-year relapse rate of 20% compared with 47% for those undergoing an auto-SCT. The PFS at 5 years was 57% for patients receiving a RIST compared with 48% for those receiving an auto-SCT. There was no significant difference in OS between the two groups. RIST is associated with a higher NRM and lower relapse rate in patients with relapsed FL.
authors.affiliation: BMT Unit, Bristol Children's Hospital, Bristol, UK.
authors.forename: S P
authors.initials: SP
authors.lastname: Robinson
authors.forename: C
authors.initials: C
authors.lastname: Canals
authors.forename: J J
authors.initials: JJ
authors.lastname: Luang
authors.forename: H
authors.initials: H
authors.lastname: Tilly
authors.forename: C
authors.initials: C
authors.lastname: Crawley
authors.forename: J Y
authors.initials: JY
authors.lastname: Cahn
authors.forename: D
authors.initials: D
authors.lastname: Pohlreich
authors.forename: S
authors.initials: S
authors.lastname: Le Gouill
authors.forename: M
authors.initials: M
authors.lastname: Gilleece
authors.forename: N
authors.initials: N
authors.lastname: Milpied
authors.forename: M
authors.initials: M
authors.lastname: Attal
authors.forename: P
authors.initials: P
authors.lastname: Biron
authors.forename: S
authors.initials: S
authors.lastname: Maury
authors.forename: A
authors.initials: A
authors.lastname: Rambaldi
authors.forename: J
authors.initials: J
authors.lastname: Maertens
authors.forename: S
authors.initials: S
authors.lastname: Capria
authors.forename: P
authors.initials: P
authors.lastname: Colombat
authors.forename: S
authors.initials: S
authors.lastname: Montoto
authors.forename: A
authors.initials: A
authors.lastname: Sureda
mesh_terms: D000328:Adult; D000368:Aged; D018450:Disease Progression; D018572:Disease-Free Survival; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods*; D006801:Humans; D008224:Lymphoma, Follicular / Q000601:surgery / Q000628:therapy*; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local; D011446:Prospective Studies; D019172:Transplantation Conditioning / Q000379:methods*; D016896:Treatment Outcome; D055815:Young Adult